Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma

BMC Cancer

Volumn 9, Issue , 2009, Pages 292-

  Pretscher, Dominik ^a   Distel, Luitpold V ^a   Grabenbauer, Gerhard G ^a   Wittlinger, Michael ^a   Buettner, Maike ^a   Niedobitek, Gerald ^a,b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNFALLKRANKENHAUS BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD3 ANTIBODY; CD68 ANTIGEN; GRANZYME B; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; HYPOPHARYNX CARCINOMA; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPH NODE METASTASIS; MALE; NECK DISSECTION; OROPHARYNX CARCINOMA; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY;

ADULT; AGED; ANTIGENS, CD20; ANTIGENS, CD80; B-LYMPHOCYTES; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PHARYNGEAL NEOPLASMS;

EID: 70349881470     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-292     Document Type: Article

References (33)

1. Uppaluri R, Dunn GP, Lewis JS. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 2008, 8:16.
2. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27(45):5904-12. 10.1038/onc.2008.271, 18836471.
3. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003, 63(7):1555-9.
4. Eerola AK, Soini Y, Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 2000, 6(5):1875-81.
5. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58(16):3491-4.
6. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102(51):18538-43. 10.1073/pnas.0509182102, 1311741,1311741, 16344461.
7. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009, 69(5):2000-9. 10.1158/0008-5472.CAN-08-2360, 19244125.
8. Zinkernagel RM. Immunity against solid tumors?. Int J Cancer 2001, 93(1):1-5. 10.1002/ijc.1305, 11391613.
9. Gannon PO, Alam Fahmy M, Begin LR, Djoukhadjian A, Filali-Mouhim A, Lapointe R. Presence of prostate cancer metastasis correlates with lower lymph node reactivity. Prostate 2006, 66(16):1710-20. 10.1002/pros.20466, 16955408.
10. Kawaida H, Kono K, Takahashi A, Sugai H, Mimura K, Miyagawa N. Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 2005, 124(1):151-7. 10.1016/j.jss.2004.10.004, 15734494.
11. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005, 2(9):e284. 10.1371/journal.pmed.0020284, 1198041,1198041, 16124834.
12. Li G, Sturgis EM. The role of human papillomavirus in squamous carcinoma of the head and neck. Curr Oncol Rep 2006, 8(2):130-9. 10.1007/s11912-006-0048-y, 16507223.
13. Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, Hille JJ. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 2005, 29(2):167-78. 10.1097/01.pas.0000149687.90710.21, 15644773.
14. Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005, 23(35):8932-41. 10.1200/JCO.2005.02.0206, 16219933.
15. Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA. Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J 2007, 86(8):506-11.
16. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006, 12(2):465-72. 10.1158/1078-0432.CCR-05-1886, 16428488.
17. Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006, 66(18):9281-9. 10.1158/0008-5472.CAN-06-0488, 16982773.
18. Verastegui E, Morales R, Barrera JL, Mueller A, Guzman B, Meneses A. Immunological approach in the evaluation of regional lymph nodes of patients with squamous cell carcinoma of the head and neck. Clin Immunol 2002, 102(1):37-47. 10.1006/clim.2001.5130, 11781066.
19. Nzula S, Going JJ, Stott DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 2003, 63(12):3275-80.
20. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008, 68(13):5405-13. 10.1158/0008-5472.CAN-07-5206, 18593943.
21. van Herpen CM, Voort R, Laak JA, Klasen IS, de Graaf AO, van Kempen LC. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int J Cancer 2008, 123(10):2354-61. 10.1002/ijc.23756, 18729197.
22. Fietkau RLC, Sauer R, Dunst J, Becker A, Baumann M, Wendt T, Grüschow K, Hess C, Budach V, Iro H. Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96-3. Journal of Clinical Oncology 2006, 24:5507. ASCO Annual Meeting Proceedings (Post-Meeting Edition).
23. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006, 12(11 Pt 1):3355-60. 10.1158/1078-0432.CCR-05-2434, 16740757.
24. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005, 11(4):1467-73. 10.1158/1078-0432.CCR-04-1869, 15746048.
25. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10(9):942-9. 10.1038/nm1093, 15322536.
26. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007, 13(3):902-11. 10.1158/1078-0432.CCR-06-2363, 17289884.
27. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006, 55(9):1064-71. 10.1007/s00262-005-0092-8, 16328385.
28. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006, 108(9):2957-64. 10.1182/blood-2006-04-018218, 16825494.
29. Ochsenbein AFKP, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999, 96:2233-2238. 10.1073/pnas.96.5.2233, 26766, 10051624.
30. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008, 100(6):407-20. 10.1093/jnci/djn025, 18334711.
31. Cochran AJ, Pihl E, Wen DR, Hoon DS, Korn EL. Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. J Natl Cancer Inst 1987, 78(3):399-405.
32. Shinkal H, Kitayama J, Kimura W, Muto T, Shibata Y. Functional expression of CD11a on CD8+ cells is suppressed in regional lymph nodes with cancer involvement in patients with gastrointestinal carcinoma. Cancer 1996, 78(8):1677-85. 10.1002/(SICI)1097-0142(19961015)78:8<1677::AID-CNCR7>3.0.CO;2-B, 8859180.
33. Balkwill FMA. Inflammation and cancer: back to Virchow?. Lancet 2001, 539-45. 11229684, 10.1016/S0140-6736(00)04046-0.